News >

Degarelix May Reduce Risk of Cardiovascular Events in Prostate Cancer

Angelica Welch
Published: Tuesday, Feb 27, 2018

Susan F. Slovin, MD, PhD
Susan F. Slovin, MD, PhD
Preliminary data suggest that patients with cardiovascular disease being treated for metastatic prostate cancer may experience fewer cardiovascular events when treated with a GnRH antagonist, such as degarelix (Firmagon), compared with a GnRH agonist.

, Susan F. Slovin, MD, PhD, the co-principal investigator of PRONOUNCE and a medical oncologist at Memorial Sloan Kettering Cancer Center, discussed this multinational study and how the results may affect the treatment of patients with prostate cancer.

OncLive: Can you first describe the difference between an agonist and an antagonist?

Slovin: A GnRH agonist, such as leuprolide, essentially tells the brain not to send a signal to the gonads to make testosterone. Because there is a feedback loop between the brain and the gonads, the gonads immediately start to make more testosterone to try to get the attention on the brain and say, "Here I am. Tell me what to do." Over a period of time, that connection just does not happen. The testes shut down, and it also has to do with follicle-stimulating and luteinizing hormones, but the point is that, at the end of the day, the testes do not receive that signal. They shut down, and the man goes through the equivalent of a chemically induced menopause.

GnRH antagonists, such as degarelix, work very differently, as they bypass that time where that surge occurs. There is no surge [in testosterone] and castration can take place within the next 24 to 48 hours. With a GnRH agonist, it takes considerably longer. If patients come in and you want to treat them rapidly, you would use an antagonist. It seems to work much faster in getting that testosterone level down and it’s well tolerated. Again, it is user’s choice—we are not saying that one is better than the other in terms of getting the job done regarding castration. The mechanism of action is a little bit different, but they both get the job done in terms of castration.  

Please provide some background on the PRONOUNCE study.

Cardiovascular disease is still a leading cause of death in men and women. Several years ago, it came under evaluation by a variety of physicians—including radiation oncologists and urologists—that there may be some increased risk of cardiovascular events, such as myocardial infarction and strokes, in patients who are receiving a GnRH agonist, such as leuprolide, which is currently being used for the treatment of metastatic prostate cancer.

This was taken very seriously in both in the United States and Europe, such that black box warnings were listed on the products to indicate that there may be a disadvantage in giving patients these drugs because it could increase cardiovascular events. This is not considering that men who have metastatic prostate cancer are often older, have preexisting cardiovascular problems, hypertension, and diabetes, in addition to having had some sort of previous cardiovascular event—these are people who are at high risk. 

Therefore, we asked, “Is there any background to this—is this a real event or not?” This was largely based on observational and retrospective studies that were done by radiation oncologists and a variety of other physicians to indicate that there was a very high risk. Given now that we have new drugs, particularly a GnRH antagonist degarelix, preliminary data have suggested that the amount of cardiovascular side effects in men receiving a GnRH antagonist might be fewer than men who receive a GnRH agonist. Very simply put, is it better to take a drug that does not allow a flare in testosterone levels to occur? 

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Publication Bottom Border
Border Publication